Literature DB >> 10604242

Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans.

P Brown1, L Cervenáková, L M McShane, P Barber, R Rubenstein, W N Drohan.   

Abstract

BACKGROUND: Solid evidence from experimentally infected animals and fragmentary evidence from naturally infected humans indicate that blood may contain low levels of the infectious agent of Creutzfeldt-Jakob disease (CJD), yet blood components have never been identified as a cause of CJD in humans. STUDY DESIGN AND METHODS: Blood components and plasma fractions were prepared from the pooled blood of mice that had earlier been infected with a mouse-adapted strain of human transmissible spongiform encephalopathy (TSE). Infectivity bioassays were conducted in healthy mice, and the brains of all assay animals dying during the course of the experiments were examined for the presence of proteinase-resistant protein.
RESULTS: Infectivity in the blood during the preclinical phase of disease occurred in the buffy coat at infectious unit (IU) levels between 6 and 12 per mL and was either absent or present in only trace amounts in plasma and plasma fractions. Infectivity rose sharply at the onset of clinical signs to levels of approximately 100 IU per mL of buffy coat, 20 IU per mL of plasma, 2 IU per mL of cryoprecipitate, and less than 1 IU per mL of fractions IV and V. Plasma infectivity was not eliminated by either white cell-reduction filtration or high-speed centrifugation. Approximately seven times more plasma and five times more buffy coat were needed to transmit disease by the intravenous route than by the intracerebral route.
CONCLUSION: Epidemiologic evidence of the absence in humans of disease transmission from plasma components can probably be explained by 1) the absence of significant plasma infectivity until the onset of symptomatic disease, and comparatively low levels of infectivity during the symptomatic stage of disease; 2) the reduction of infectivity during plasma processing; and 3) the need for at least five to seven times more infectious agent to transmit disease by the intravenous than intracerebral route. These and other factors probably also account for the absence of transmission after the administration of whole blood or blood components.

Entities:  

Mesh:

Year:  1999        PMID: 10604242     DOI: 10.1046/j.1537-2995.1999.39111169.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  43 in total

1.  Scrapie infectivity in hamster blood is not associated with platelets.

Authors:  Karel Holada; Jaroslav G Vostal; Patrick W Theisen; Claudia MacAuley; Luisa Gregori; Robert G Rohwer
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

2.  PrP(Sc) is not detected in peripheral blood leukocytes of scrapie-infected sheep: determining the limit of sensitivity by immunohistochemistry.

Authors:  Lynn M Herrmann; Timothy V Baszler; Donald P Knowles; William P Cheevers
Journal:  Clin Diagn Lab Immunol       Date:  2002-03

3.  Report of the Working Group 'Overall Blood Supply Strategy with Regard to Variant Creutzfeldt-Jakob Disease (vCJD)': Statement on the Development and Implementation of Test Systems Suitable for the Screening of Blood Donors for vCJD - Dated September 17, 2008.

Authors: 
Journal:  Transfus Med Hemother       Date:  2009       Impact factor: 3.747

4.  First demonstration of transmissible spongiform encephalopathy-associated prion protein (PrPTSE) in extracellular vesicles from plasma of mice infected with mouse-adapted variant Creutzfeldt-Jakob disease by in vitro amplification.

Authors:  Paula Saá; Oksana Yakovleva; Jorge de Castro; Irina Vasilyeva; Silvia H De Paoli; Jan Simak; Larisa Cervenakova
Journal:  J Biol Chem       Date:  2014-08-25       Impact factor: 5.157

Review 5.  Molecular neurology of prion disease.

Authors:  J Collinge
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-07       Impact factor: 10.154

6.  Novel cryoprecipitate for wound healing and skin grafts in rats.

Authors:  Thomas Scholz; Joshua Waltzman; Garrett A Wirth; Senait W Dyson; William J Owens; Edward Shanbrom; Gregory R D Evans
Journal:  Int Wound J       Date:  2008-10       Impact factor: 3.315

7.  BSE safety standards: An evaluation of public health policies of Japan, Europe, and USA.

Authors:  Gino C Matibag; Manabu Igarashi; Hiko Tamashiro
Journal:  Environ Health Prev Med       Date:  2005-09       Impact factor: 3.674

8.  Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy.

Authors:  Angiola Rocino; Antonio Coppola; Massimo Franchini; Giancarlo Castaman; Cristina Santoro; Ezio Zanon; Elena Santagostino; Massimo Morfini
Journal:  Blood Transfus       Date:  2014-10       Impact factor: 3.443

9.  B cells and platelets harbor prion infectivity in the blood of deer infected with chronic wasting disease.

Authors:  Candace K Mathiason; Jeanette Hayes-Klug; Sheila A Hays; Jenny Powers; David A Osborn; Sallie J Dahmes; Karl V Miller; Robert J Warren; Gary L Mason; Glenn C Telling; Alan J Young; Edward A Hoover
Journal:  J Virol       Date:  2010-03-10       Impact factor: 5.103

10.  Prion proteins in subpopulations of white blood cells from patients with sporadic Creutzfeldt-Jakob disease.

Authors:  Ed M Choi; Michael D Geschwind; Camille Deering; Kristen Pomeroy; Amy Kuo; Bruce L Miller; Jiri G Safar; Stanley B Prusiner
Journal:  Lab Invest       Date:  2009-06       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.